Randomized phase III TRIAL COMPARING FOLFIRINOX (F: 5FU/LEUCOVORIN [LV], IRINOTECAN [1], AND OXALIPLATIN [O]) versus gemcitabine (G) as first-line treatment for metastatic pancreatic adenocarcinoma (MPA): Preplanned interim analysis results of the PRODIGE 4/ACCORD 11 trial

被引：29
|
作者：
Conroy, T.
Desseigne, F.
Ychou, M.
Ducreux, M.
Bouche, O.
Guimbaud, R.
Becouarn, Y.
Montoto-Grillot, C.
Gourgou-Bourgade, S.
Adenis, A.
机构：
[1] Ctr Alexis Vautrin, Vandoeuvre Les Nancy, France
[2] Ctr Leon Berard, F-69373 Lyon, France
[3] Ctr Val Aurelle, Montpellier, France
[4] Inst Gustave Roussy, Villejuif, France
[5] Univ Hosp Robert Debre, Reims, France
[6] Univ Hosp Purpan, Toulouse, France
[7] Inst Bergonie, Bordeaux, France
[8] Federat Natl Ctr Lutte Canc, Paris, France
[9] Ctr Oscar Lambret, F-59020 Lille, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
10.1200/jco.2010.28.15_suppl.4010
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4010
引用
收藏
页数：1
相关论文
共 35 条
  • [31] 5-fluorouracil and oxaliplatin with or without docetaxel in the first-line treatment of HER2 negative locally advanced (LA) unresectable or metastatic gastric or gastro-esophageal junction (GEJ) adenocarcinoma (GASTFOX-PRODIGE 51): A randomized phase III trial sponsored by the FFCD
    Zaanan, A.
    Bouche, O.
    De la Fouchardiere, C.
    Samalin-Scalzi, E.
    Le Malicot, K.
    Pernot, S.
    Artru, P.
    Lebrun, V. Ly
    Aldabbagh, K.
    Akouz, F. Khemissa
    Castanie, H.
    Laly, M.
    Botsen, D.
    Muller, M.
    Roth, G.
    Lecomte, T.
    Phelip, J. M.
    Lepage, C.
    Louvet, C.
    ANNALS OF ONCOLOGY, 2023, 34 : S1318 - S1318
  • [32] Phase III, randomized, open-label study of capecitabine (X) plus oxaliplatin (XELOX) vs. infusional 5-FU/LV plus oxaliplatin (FOLFOX-6) first-line treatment in patients (pts) with metastatic colorectal cancer (MCRC): Findings from an interim safety analysis.
    Ducreux, M
    Adenis, A
    Bennouna, J
    Conroy, T
    Faroux, R
    Hebbar, M
    Lledo, G
    Paillot, B
    Ychou, M
    Douillard, JY
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 270S - 270S
  • [33] Analysis of consensus molecular subtypes (CMS) classification in the TRICOLORE trial: A randomized phase III trial of S-1 and irinotecan (IRI) plus bevacizumab (Bmab) versus mFOLFOX6 or CapeOX plus Bmab as first-line treatment for metastatic colorectal cancer (mCRC)
    Yuki, Satoshi
    Gamoh, Makio
    Denda, Tadamichi
    Takashima, Atsuo
    Takahashi, Shin
    Nakamura, Masato
    Ohori, Hisatsugu
    Yamaguchi, Tatsuro
    Kobayashi, Yoshimitsu
    Baba, Hideo
    Kotake, Masanori
    Amagai, Kenji
    Kondo, Hitoshi
    Shimada, Ken
    Sato, Atsushi
    Ishioka, Chikashi
    Komine, Keigo
    Ouchi, Kota
    Morita, Satoshi
    Komatsu, Yoshito
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [34] First line infusion of 5-fluorouracil, leucovorin and oxaliplatin for metastatic colorectal cancer :: 4-day chronomodulated (FFI-4-10) versus 2-day FOLFOX2.: A multicenter randomized Phase III trial of the Chronotherapy Group of the European Organization for Research and Treatment of Cancer [EORTC 05963).
    Giacchetti, S
    Bjarnason, G
    Garufi, C
    Tubiana-Mathieu, N
    Iacobelli, S
    Dogliotti, L
    Smaaland, R
    Focan, C
    Coudert, B
    Lévi, F
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 251S - 251S
  • [35] Final overall survival (OS) results of CONFIRM 1 (CF1), a randomized, double-blind, placebo-controlled phase III trial in patients with metastatic adenocarcinoma of the colon or rectum (mCRC) receiving first line chemotherapy with oxaliplatin/5-fluorouracil/Leucovorin (FOLFOX 4) and PTK787/ZK 222584 (PTK/ZK) or placebo (PBO)
    Hecht, J. R.
    Trarbach, T.
    Jaeger, E.
    Hainsworth, J.
    Wolff, R. A.
    Lloyd, K.
    Bodoky, G.
    Borner, M.
    Laurent, D.
    Jacques, C.
    EJC SUPPLEMENTS, 2007, 5 (04): : 238 - 238
1234